Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$30.89M$30.89M+31.9% vs Q1 2022 Net Income-$86.33M-$86.33MN/M vs Q1 2022 EPS Diluted-$1.27-$1.27N/M vs Q1 2022 Operating Income-$97,369,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$81,747,000N/M Margins · derivedOperating margin-315.2%−7.8 pt vs Q1 2022
Net margin-279.5%+45.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end